Impact of platelet activating factor on vascular responsiveness in isolated rat lungs. 1986

M N Gillespie, and B D Bowdy

Platelet activating factor (PAF), a suspected mediator of acute lung injury, has been shown to potentiate contraction in isolated porcine carotid arteries. Such an action of PAF, if it occurred in the pulmonary circulation, could be of significance to the evolution of pulmonary hypertension in acute lung injury. Accordingly, we used isolated rat lungs perfused at a constant flow rate with physiologic salt solution to test the hypothesis that PAF-induced lung injury is associated with pulmonary vascular hyperresponsiveness to constrictor stimuli. PAF in concentrations of 0.1 to 10 ng/ml failed to influence pressor responses evoked by i.a. bolus injections of angiotensin II (Ang II) whereas 1 micrograms/ml of PAF significantly blunted Ang II-induced vasoconstriction. Similarly, 1 micrograms/ml, but not 0.1 ng/ml, of PAF attenuated constriction induced by ventilation with 3% O2. PAF at all concentrations tested failed to influence pressor responses evoked by i.a. bolus injections of KCI. Concentrations of PAF which blunted Ang II and hypoxic responses were associated with increased lung wet-to-dry weight ratios indicative of pulmonary edema. Another agent that provokes edema, cytochalasin B, also increased lung wet-to-dry weight ratios and blunted Ang II-, hypoxia-, and KCI-induced pressor responses. PAF delivered as i.a. bolus injections caused acute vasodilation in preparations preconstricted with Ang II but not in those preconstricted with KCI. Collectively, these observations demonstrate that PAF fails to augment and instead blunts pulmonary vascular responsiveness to pressor stimuli, possibly by mechanisms that relate to PAF-induced edema formation and/or vasodilation.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D011189 Potassium Chloride A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA. Slow-K,Chloride, Potassium
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D003571 Cytochalasin B A cytotoxic member of the CYTOCHALASINS. Phomin
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M N Gillespie, and B D Bowdy
November 1988, Journal of applied physiology (Bethesda, Md. : 1985),
M N Gillespie, and B D Bowdy
December 1991, Circulatory shock,
M N Gillespie, and B D Bowdy
January 1990, Proceedings of the Western Pharmacology Society,
M N Gillespie, and B D Bowdy
November 1989, The American journal of physiology,
M N Gillespie, and B D Bowdy
January 1981, Respiration; international review of thoracic diseases,
M N Gillespie, and B D Bowdy
June 1987, The Journal of clinical investigation,
M N Gillespie, and B D Bowdy
July 1993, The American review of respiratory disease,
M N Gillespie, and B D Bowdy
January 1994, Journal of vascular research,
Copied contents to your clipboard!